A new study found that 1 in 3 rheumatoid arthritis patients with normal heart function on standard tests had hidden heart strain detectable only through advanced imaging, with anemia emerging as the strongest predictor.
Selarsdi (ustekinumab-aekn) was approved by the FDA as an interchangeable biosimilar to Stelara (ustekinumab) for all approved indications, including psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis.
A new single-dose chikungunya vaccine produced strong immune responses in nearly all adolescents and adults in a large clinical trial, with mild and short-lived side effects.
April’s FDA approvals feature first-in-class therapies, targeted biologics, expanded indications, and innovative delivery systems across allergy, endocrinology, rheumatology, oncology, infectious diseases, and more.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
The first FcRn blocker for both adult and pediatric generalized myasthenia gravis has been approved by the FDA, based on data showing sustained symptom improvement and IgG reduction in clinical trials.
A new AI-assisted gold sensor distinguished osteoarthritis from rheumatoid arthritis with 98.1% accuracy by analyzing synovial fluid, offering a fast, noninvasive diagnostic option, researchers report.